Caliper’s Revenues Shoot Up, but Losses Stay Flat in Q1

Caliper Life Sciences last week reported a three-fold revenue increase year-over-year for the first quarter of 2004, while losses remained stable. Revenues were $16.9 million, up from $5.6 million during the same period last year. This increase was mainly due to revenues from Zymark, which Caliper acquired last July.

R&D expenses decreased to $6.5 million, from $9.4 million during the same quarter in 2003.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.